» Articles » PMID: 10582875

Activities of Tobramycin and Six Other Antibiotics Against Pseudomonas Aeruginosa Isolates from Patients with Cystic Fibrosis

Overview
Specialty Pharmacology
Date 1999 Dec 3
PMID 10582875
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The in vitro activity of tobramycin was compared with those of six other antimicrobial agents against 1,240 Pseudomonas aeruginosa isolates collected from 508 patients with cystic fibrosis during pretreatment visits as part of the phase III clinical trials of tobramycin solution for inhalation. The tobramycin MIC at which 50% of isolates are inhibited (MIC(50)) and MIC(90) were 1 and 8 microg/ml, respectively. Tobramycin was the most active drug tested and also showed good activity against isolates resistant to multiple antibiotics. The isolates were less frequently resistant to tobramycin (5.4%) than to ceftazidime (11.1%), aztreonam (11.9%), amikacin (13.1%), ticarcillin (16.7%), gentamicin (19.3%), or ciprofloxacin (20.7%). For all antibiotics tested, nonmucoid isolates were more resistant than mucoid isolates. Of 56 isolates for which the tobramycin MIC was > or = 16 microg/ml and that were investigated for resistance mechanisms, only 7 (12.5%) were shown to possess known aminoglycoside-modifying enzymes; the remaining were presumably resistant by an incompletely understood mechanism often referred to as "impermeability."

Citing Articles

The Impact of Antimicrobial Resistance in Cystic Fibrosis.

Vitiello A, Blasi F, Sabbatucci M, Zovi A, Miele F, Ponzo A J Clin Med. 2024; 13(6).

PMID: 38541936 PMC: 10970943. DOI: 10.3390/jcm13061711.


Assessment of the Glycan-Binding Profile of Pseudomonas aeruginosa PAO1.

Sanchez H, OToole G, Berwin B Microbiol Spectr. 2023; 11(4):e0166723.

PMID: 37470715 PMC: 10434018. DOI: 10.1128/spectrum.01667-23.


Assessment of the Glycan-Binding Profile of PAO1.

Sanchez H, OToole G, Berwin B bioRxiv. 2023; .

PMID: 37131708 PMC: 10153242. DOI: 10.1101/2023.04.20.537720.


Codelivery of synergistic antimicrobials with polyelectrolyte nanocomplexes to treat bacterial biofilms and lung infections.

Finbloom J, Raghavan P, Kwon M, Kharbikar B, Yu M, Desai T Sci Adv. 2023; 9(3):eade8039.

PMID: 36662850 PMC: 9858510. DOI: 10.1126/sciadv.ade8039.


Synergistic interaction of cuminaldehyde and tobramycin: a potential strategy for the efficient management of biofilm caused by Pseudomonas aeruginosa.

Chatterjee S, Das S, Paul P, Chakraborty P, Sarkar S, Das A Folia Microbiol (Praha). 2022; 68(1):151-163.

PMID: 36192618 DOI: 10.1007/s12223-022-01005-z.


References
1.
Thomassen M, Demko C, BOXERBAUM B, Stern R, Kuchenbrod P . Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979; 140(6):873-80. DOI: 10.1093/infdis/140.6.873. View

2.
Burns J, Van Dalfsen J, Shawar R, Otto K, Garber R, Quan J . Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis. 1999; 179(5):1190-6. DOI: 10.1086/314727. View

3.
Gordts B, Vandenborre C, Vanderauwera P, Butzler J . Comparison between the in-vitro activity of new agents on Pseudomonas aeruginosa isolates from cystic fibrosis patients and other chronic infections. J Antimicrob Chemother. 1984; 14(1):25-9. DOI: 10.1093/jac/14.1.25. View

4.
Gerding D, Larson T . Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985. Am J Med. 1986; 80(6B):22-8. DOI: 10.1016/0002-9343(86)90475-4. View

5.
Lester A, Andreasen J . In vitro susceptibility of Pseudomonas aeruginosa from bacteremic and fibrocystic patients to four quinolones and five other antipseudomonal antibiotics. Scand J Infect Dis. 1988; 20(5):525-9. DOI: 10.3109/00365548809032501. View